Rigel Pharmaceuticals Inc expected to post earnings of $2.58 a share - Earnings Preview

Rigel Pharmaceuticals

01/08/2025 23:49

Rigel Pharmaceuticals Inc RIGL.OQ RIGL.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 for the period ending June 30 2025

The South San Francisco California-based  company is expected to report a 141.4% increase in revenue to $88.947 million from $36.84 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data. (Majority Basis Includes Non-Cash Revenue Gain.)

​LSEG's mean analyst estimate for Rigel Pharmaceuticals Inc is for earnings of $2.58 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc is $23.50, about 6.8% above its last closing price of $21.91

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
0.04
0.09
0.63
Beat
606.3
Dec. 31 2025
0.59
0.47
0.80
Beat
71.3
Sep. 30 2024
0.08
0.06
0.70
Beat
1,100.1​
Jun. 30 2024
-0.28
-0.29
-0.06
Beat
79.5
​​Mar. 31 2024
-0.27
-0.29
-0.50
Missed
-73.4
Dec. 31 2023
-0.27
-0.30
0.00
Beat
100​
Sep. 30 2023
-0.72
-0.71
-0.30
Beat
57.7
Jun. 30 2023
-0.78
-0.78
-0.40
Beat
48.7

This summary was machine generated August 1 at 22:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)